Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST-Fish: SCIT for Fish Allergy
NCT02017626Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Aug 2013
- Primary completion
- Oct 2014
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mutant carp parvalbumin in fish allergy (2 arms), sponsored by Rigshospitalet. Primary endpoint: Safety in the form of number and severity of adverse events at 1 year. Started Aug 2013; status: completed.
02
Drugs
mutant carp parvalbumin
03
Conditions
fish allergy
Beyond the preview
Go deeper on NCT02017626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02017626.